down arrow

Syros Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87184Q2066
USD
0.00
0.00 (0.00%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.31
Valuation
Technical
Day's Volume

CASH

4.38 k

Shareholding (Sep 2024)

FII

11.68%

Held by 22 FIIs

DII

38.16%

Held by 8 DIIs

Promoter

44.72%

How big is Syros Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Syros Pharmaceuticals, Inc. has a market capitalization of 0.64 million, with net sales of 0.39 million and a net profit of -97.82 million over the last four quarters. As of Dec'23, the company reported shareholder's funds of 16.66 million and total assets of 168.17 million.

Market Cap: As of Jun 18, Syros Pharmaceuticals, Inc. has a market capitalization of 0.64 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Syros Pharmaceuticals reported net sales of 0.39 million and a net profit of -97.82 million.<BR><BR>Balance Sheet Snapshot: As of Dec'23, the company reported shareholder's funds of 16.66 million and total assets of 168.17 million.

Read More

What does Syros Pharmaceuticals, Inc. do?

22-Jun-2025

Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing gene control medicines for cancer and monogenic diseases. As of September 2024, it has a market cap of $0.64 million and reported a net profit of -$6 million.

Overview:<BR>Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing gene control medicines for cancer and monogenic diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -6 Million (Quarterly Results - Sep 2024)<BR>Market cap: USD 0.64 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 1.31<BR>Return on Equity: 1,008.24%<BR>Price to Book: -0.06<BR><BR>Contact Details:<BR>Address: 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA: 02140<BR>Tel: 1 617 7441340<BR>Fax: 1 617 7441377<BR>Website: https://syros.com/

Read More

Who are in the management team of Syros Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Syros Pharmaceuticals, Inc. includes Independent Chairman Mr. Peter Wirth, President and CEO Dr. Nancy Simonian, and Directors Dr. S. Gail Eckhardt, Dr. Richard Young, Dr. Srinivas Akkaraju, Mr. Mark Alles, and Ms. Marsha Fanucci. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Syros Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Peter Wirth, who serves as the Independent Chairman of the Board.<BR>- Dr. Nancy Simonian, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. S. Gail Eckhardt, who is a Director.<BR>- Dr. Richard Young, who is also a Director.<BR>- Dr. Srinivas Akkaraju, serving as an Independent Director.<BR>- Mr. Mark Alles, who is an Independent Director.<BR>- Ms. Marsha Fanucci, who is an Independent Director.<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is Syros Pharmaceuticals, Inc. technically bullish or bearish?

25-Jun-2025

As of March 5, 2025, Syros Pharmaceuticals, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators present mixed signals, suggesting a cautious outlook.

As of 5 March 2025, the technical trend for Syros Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while the weekly MACD shows a mildly bullish signal. The Bollinger Bands are sideways on the weekly chart, and the KST is mildly bullish weekly but bearish monthly. Overall, the lack of strong bullish signals and the presence of bearish indicators suggest a cautious outlook.

Read More

Is Syros Pharmaceuticals, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, Syros Pharmaceuticals, Inc. is considered to have significant financial concerns and is overvalued, with poor performance metrics and a year-to-date decline of 99.74%, contrasting sharply with the S&P 500's 12.22% gain.

As of 8 July 2024, the valuation grade for Syros Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of -0.06, an EV to EBIT of 0.12, and an EV to EBITDA of 0.13, which suggest that the company is not generating adequate returns relative to its enterprise value. <BR><BR>In comparison to its peers, Syros Pharmaceuticals has a less favorable EV to EBITDA ratio than Avrobio, Inc. at -2.5908 and Elicio Therapeutics, Inc. at -4.1277, highlighting its struggles in the market. The company's returns have been dismal, with a year-to-date decline of -99.74% compared to a 12.22% gain in the S&P 500, reinforcing the notion that it is significantly underperforming relative to broader market trends.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.31

stock-summary
Return on Equity

1,008.24%

stock-summary
Price to Book

-0.01

Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2024)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-54.55%
0%
-54.55%
6 Months
-98.07%
0%
-98.07%
1 Year
-99.8%
0%
-99.8%
2 Years
-99.98%
0%
-99.98%
3 Years
-99.99%
0%
-99.99%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Syros Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Syros Pharmaceuticals, Inc. overvalued or undervalued?

As of 8 July 2024, the valuation grade for Syros Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of -0.06, an EV to EBIT of 0.12, and an EV to EBITDA of 0.13, which suggest that the company is not generating adequate returns relative to its enterprise value. In comparison to its peers, Syros Pharmaceuticals has a less favorable EV to EBITDA ratio than Avrobio, Inc. at -2.5908 and Elicio Therapeutics, Inc. at -4.1277, highlighting its struggles in the market. The company's returns have been dismal, with a year-to-date decline of -99.74% compared to a 12.22% gain in the S&P 500, reinforcing the notion that it is significantly underperforming relative to broader market trends....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-30.30%
EBIT Growth (5y)
-11.72%
EBIT to Interest (avg)
-36.10
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.31
Sales to Capital Employed (avg)
0.12
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
95.36%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.06
EV to EBIT
0.12
EV to EBITDA
0.13
EV to Capital Employed
0.54
EV to Sales
-13.93
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
433.39%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 7 Schemes (5.44%)

Foreign Institutions

Held by 22 Foreign Institutions (11.68%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 72.53% vs -529.73% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.90",
          "val2": "-27.10",
          "chgp": "4.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "1.40",
          "chgp": "-7.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "20.30",
          "val2": "4.40",
          "chgp": "361.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.40",
          "val2": "-23.30",
          "chgp": "72.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -33.56% vs -36.60% in Dec 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -73.81% vs -9.35% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.90",
          "val2": "14.90",
          "chgp": "-33.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-124.20",
          "val2": "-123.40",
          "chgp": "-0.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5.10",
          "val2": "4.10",
          "chgp": "24.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-39.80",
          "val2": "33.70",
          "chgp": "-218.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-164.60",
          "val2": "-94.70",
          "chgp": "-73.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-12,731.40%",
          "val2": "-8,492.10%",
          "chgp": "-423.93%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQstock-summary
Sep'24
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-25.90
-27.10
4.43%
Interest
1.30
1.40
-7.14%
Exceptional Items
20.30
4.40
361.36%
Consolidate Net Profit
-6.40
-23.30
72.53%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2024 is 72.53% vs -529.73% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
9.90
14.90
-33.56%
Operating Profit (PBDIT) excl Other Income
-124.20
-123.40
-0.65%
Interest
5.10
4.10
24.39%
Exceptional Items
-39.80
33.70
-218.10%
Consolidate Net Profit
-164.60
-94.70
-73.81%
Operating Profit Margin (Excl OI)
-12,731.40%
-8,492.10%
-423.93%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -33.56% vs -36.60% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -73.81% vs -9.35% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Syros Pharmaceuticals, Inc. stock-summary
stock-summary
Syros Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefining the power of small molecules to control the expression of genes. It is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a selective retinoic acid receptor alpha (RAR), agonist that is being evaluated in combination with azacytidine, used to treat acute myeloid leukemia (AML). SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors. SY-2101 is an oral form of arsenic trioxide (ATO) being developed for the treatment of AML.
Company Coordinates stock-summary
Company Details
35 CAMBRIDGE PARK DRIVE , CAMBRIDGE MA : 02140
stock-summary
Tel: 1 617 7441340
stock-summary
https://syros.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."